This post was originally published on this site The U.S. Food and Drug Administration (FDA) has accepted for review BeiGene‘s application requesting the approval of zanubrutinib for treating people with mantle cell lymphoma who received at least one prior therapy. BeiGene’s new drug application (NDA) received priority review status, which reduces review time from the…
About Cancer
Cancer, also called malignancy, is an abnormal growth of cells with the potential to invade or spread to surrounding tissues and structures found within the body. There are more than 100 types of cancer. A few examples include breast cancer, skin cancer, lung cancer, colon cancer, prostate cancer, and lymphoma. According to the American Cancer Society, 4 out of 10 people will be diagnosed with some form of cancer in their lifetime. Cancer prevalence has given rise to multiple medical specialties focused on symptom management and disease management. Current treatment options depending on the form of cancer include chemotherapy, radiation, blood or bone marrow transfusions, and/or surgery. Lifetime prognosis of cancer mortality is dependent on the type of cancer and is heavily conditional to early detection.
Conditions
Cancer News
NKTR-214 with Opdivo Earns FDA’s Breakthrough Therapy Designation for Advanced Melanoma
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation for a combination of the potential therapy NKTR-214 with Opdivo (nivolumab) for untreated melanoma patients with either metastatic disease or who are unable to undergo surgery. A global Phase 3 clinical trial (NCT03635983) comparing the effectiveness and safety…
Oral Paclitaxel Combo Leads to Better Response Rates Than IV Therapy in MBC, Data Shows
This post was originally published on this site Treatment with a combination of oral paclitaxel and encequidar led to higher and stronger response rates compared with standard paclitaxel intravenous therapy in women with metastatic breast cancer, topline data from a Phase 3 trial shows. Paclitaxel is a widely used chemotherapy agent that interferes with the molecular…
PSMA-targeted Therapies Work Best in Tumors with Mutations in DNA Repair Genes, Study Suggests
This post was originally published on this site Tumors with large numbers of prostate cancer cells with mutations in DNA repair genes are easier to target using prostate-specific membrane antigen (PSMA) therapies, and patients with these tumors are more likely to respond to this potential treatment’s use, a study found. Results from the study, “Prostate-specific Membrane…
Lymphoma Research Foundation to Honor MSK’s Anas Younes at September Gala
This post was originally published on this site The Lymphoma Research Foundation will honor Anas Younes, an oncologist and lymphoma expert at Memorial Sloan Kettering (MSK) Cancer Center, with its Distinguished Leadership Award next month at the nonprofit’s annual gala. The LRF ceremony, set for Sept. 26 in New York City, coincides with National Blood Cancer Awareness Month.…
Myriad to Seek FDA Approval of Diagnostic Test to Determine Lynparza Eligibility for mCRPC Patients
This post was originally published on this site Myriad Genetics is filing an application with the U.S. Food and Drug Administration requesting the approval of its BRACAnalysis CDx — which identifies inherited BRCA mutations — as a companion diagnostic test for selecting metastatic castration-resistant prostate cancer (mCRPC) patients eligible for Lynparza (olaparib) treatment. The announcement…
Honoring its Co-Founder’s Legacy, Newk’s Cares Kicks Off 6th Annual Ovarian Cancer Campaign
This post was originally published on this site For the sixth straight year, Newk’s Cares, the philanthropic arm of Newk’s Eatery, is raising money and awareness to battle ovarian cancer, the disease that earlier this year took the organization’s co-founder Lori Newcomb. The efforts coincide with Ovarian Cancer Awareness Month, observed each September. Chris Newcomb,…
CAR T-cell Therapy Combo Shows Promise in Treating Advanced Multiple Myeloma, Study Says
This post was originally published on this site Using a combination of CAR T-cell therapies to target different cancer molecules appears to be a feasible and promising way of treating relapsed or refractory multiple myeloma, a study reports. The findings of the study, “A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed…
Esophagogastric Cancer Patients with High DKK1 Levels Respond Better to DKN-01, Keytruda Combo, Phase 1 Trial Shows
This post was originally published on this site A combination of Leap Therapeutics‘ investigational therapy DKN-01 plus Keytruda (pembrolizumab) led to “highly encouraging” responses and survival outcomes in a population of advanced esophagogastric cancer patients with elevated levels of the Dickkopf-1 (DKK1) protein, according to preliminary results of a Phase 1 clinical trial. These results suggest…
FDA Approves Rozlytrek for Breast Cancer, Other Solid Tumors with Specific Gene Defect
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has approved Rozlytrek (entrectinib) as an oral treatment for adult and adolescent patients whose breast cancer and other solid tumors have a specific genetic defect called NTRK gene fusion, have no other satisfactory therapy, is metastatic, or likely to experience severe…
Nebraska’s Neena Nizar Seeks Cure for Jansen’s, One of World’s Rarest Diseases
This post was originally published on this site Imagine living your whole life with a painful disease so rare that only 25 others worldwide have what you have. And that you’re one of just six such people who’ve made it to adulthood. Neena Nizar doesn’t have to imagine. The 41-year-old English professor at Metro Community…
Clinical Trials in China Will Test Abexinostat for DLBCL, Follicular Lymphoma
This post was originally published on this site Xynomic Pharma is launching two pivotal clinical trials in China to test its investigational HDAC inhibitor, abexinostat, as a third-line therapy for two types of non-Hodgkin’s lymphoma: diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma, The announcement came after China’s National Medical Products Administration (NMPA) approved the trials, which will be…